Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

September 30, 2018

Conditions
HIV Risk
Interventions
DRUG

Genvoya

Oral use (one tablet each day); 150/150/200/10 mg; 28 days

Trial Locations (16)

25030

Hôpital Jean Minjoz, Besançon

33075

Hôpital Saint-André, Bordeaux

35033

CHU, Rennes

51092

CHU de Reims, Reims

57050

CHR de Metz, Metz

59208

Hôpital de Tourcoing, Tourcoing

67091

Hôpitaux Universitaires, Strasbourg

69317

Hôpital Croix Rousse, Lyon

75018

CHU Bichat, Paris

75020

Hôpital Tenon, Paris

75571

Hôpital Saint-Antoine, Paris

75651

GH Pitié Salpetriere, Paris

77908

CHU Dijon, Dijon

92100

CHU Ambroise Paré, Boulogne-Billancourt

92150

Hôpital Foch, Suresnes

08011

Hôpital Manchester, Charleville-Mézières

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux

NETWORK

NCT02998320 - Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis | Biotech Hunter | Biotech Hunter